Compare Illumina, Inc. (ILMN) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs iShares MSCI China ETF — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while iShares MSCI China ETF trades at $55.86. The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | MCHI | |
|---|---|---|
Market Cap | $28.96B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $205.10 | $66.99 |
52-Week Low | $91.00 | $50.48 |
Enterprise Value | $30.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
MCHI trades at $56.57, up 1.19% with strong technical momentum showing bullish moving averages and institutional buying interest. The ETF benefits from China's export strength and AI-driven manufacturing growth, though key financial ratios remain undisclosed. Recent news highlights China's 23% July export surge and $295 billion AI infrastructure plan, creating positive sentiment around Chinese equities.
Outlook remains cautiously optimistic with technical indicators signaling strength but RSI levels suggesting potential overbought conditions. Key risks include US-China trade tensions and regulatory uncertainties, while institutional flows and China's tech investment push provide upside catalysts for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
